Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lophius Biosciences Closes Financing Round and Expands Management Board

Published: Tuesday, January 22, 2013
Last Updated: Tuesday, January 22, 2013
Bookmark and Share
Expansion of product portfolio in the field of T-cell based diagnostics.

Lophius Biosciences announced the closing of a further financing round. With VRD GmbH and WIC GmbH two new investors will financially support the company alongside existing investors such as S-Refit, HighTech Gründerfonds (HTGF), Bayern Kapital and two Business Angels. With a commitment of about 4 Mio. EUR, Lophius Biosciences intends to fully introduce its technologies and products in the field of T-cell based diagnostics. Prof. Dr. Ralf Wagner, former CEO of GeneArt AG, has been appointed as Managing Director in order to drive the further development of the company together with the current Managing Director Dr. Michael Lutz.

Prof. Wagner was founder, CEO and CSO of Regensburg-based company GeneArt AG which specialized in the field of synthetic biology. Following the acquisition by Life Technologies in 2010 he was responsible as Site leader and Vice President Synthetic Biology for the successful integration of GeneArt AG into Life Technologies. As professor for molecular microbiology and gene therapy, Dr Wagner is also member of the Medical faculty at the University of Regensburg.

„We are very pleased that the positive development of Lophius Biosciences could be continued and even accelerated with these new funds. With their commitment, the new and existing investors have strongly validated the (recent) successful product developments for the CE-marked T-Track© CMV and EBV-Tests and T-Track© TB (Tuberculosis) based on our two patented technology platforms” said Dr. Michael Lutz, Managing Director of Lophius Biosciences.

Prof. Wagner’s strong focus will be on the successful rounding off and launch of the product portfolio together with Dr. Lutz and the whole Lophius Biosciences team. “Lophius Biosciences is a young but very innovative biotech company with the potential to become a fully integrated player in the new field of T-cell based diagnostics. Based on its proprietary know-how the company has many unique selling points for its products to provide significant diagnostic and clinical value to patients and physicians in a number of medical indications. I am happy to become part of this very interesting opportunity”, added Prof. Wagner.

„Together with the expanded management the existing investors highly welcome both VRD GmbH and WIC GmbH as new investors who strongly support the current company and investor strategy. With the addition of Prof. Wagner to the management board, the company has clearly accomplished another key milestone. Prof. Wagner and the existing Managing Director Dr. Lutz will form a strong team with outstanding expertise for developing small and medium-sized companies“, added Mr. Bertram Gilka-Bötzow, Head of Lophius Biosciences´ Advisory Board and Investment Director of S-Refit, the current Lead Investor of Lophius Biosciences.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!